Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: ANRO )

3.850 -0.100 (-2.53%)
Official Closing Price Updated: 7:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANRO

< Previous 1 2 Next >
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Nasdaq Down 2%; US Crude Stocks Increase
Via Benzinga
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies. 
Via Benzinga
Gold Moves Lower; AT&T Earnings Top Views
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
Via Benzinga
Topics Stocks
Exposures US Equities
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024
ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
From Alto Neuroscience, Inc.
Via Business Wire
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors. 
Via InvestorPlace
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
From Alto Neuroscience, Inc.
Via Business Wire
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024
ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia. 
Via Benzinga
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.